Last reviewed · How we verify
daptomycin (up to 14 days)
Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death.
Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death. Used for Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria, Staphylococcus aureus bacteremia, including right-sided endocarditis.
At a glance
| Generic name | daptomycin (up to 14 days) |
|---|---|
| Sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | Cyclic lipopeptide antibiotic |
| Target | Bacterial cell membrane |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Daptomycin is a cyclic lipopeptide antibiotic that inserts into the bacterial cell membrane in a calcium-dependent manner. This insertion disrupts the electrochemical gradient across the membrane, causing potassium efflux and depolarization. The resulting loss of membrane potential is bactericidal, making it effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).
Approved indications
- Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria
- Staphylococcus aureus bacteremia, including right-sided endocarditis
Common side effects
- Elevated creatine phosphokinase (CPK)
- Muscle pain or myopathy
- Injection site reactions
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Staphylococcus Aureus Network Adaptive Platform Trial (PHASE4)
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN (PHASE2)
- Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections (PHASE4)
- Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections (PHASE4)
- Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections (PHASE3)
- Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: